Kasra Moazzami1,2, Matthew T Wittbrodt3, Bruno B Lima1,2, Jonathon A Nye4, Puja K Mehta2, Brad D Pearce1, Zakaria Almuwaqqat1,2, Muhammad Hammadah2, Oleksiy Levantsevych2, Yan V Sun1, Paolo Raggi5, Ernest V Garcia4, Margarethe Goetz1, Arshed A Quyyumi2, J Douglas Bremner3,4,6, Viola Vaccarino1,2, Amit J Shah1,2,6. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA (K.M., B.B.L., B.D.P., Z.A., Y.V.S., M.G., V.V., A.J.S.). 2. Emory Clinical Cardiovascular Research Institute, Department of Medicine, Division of Cardiology (K.M., B.B.L., P.K.M., Z.A., M.H., O.L., A.A.Q., V.V., A.J.S.), Emory University School of Medicine, Atlanta, GA. 3. Department of Psychiatry and Behavioral Sciences (M.T.W., J.D.B.), Emory University School of Medicine, Atlanta, GA. 4. Department of Radiology and Imaging Sciences (J.A.N., E.V.G., J.D.B.), Emory University School of Medicine, Atlanta, GA. 5. Mazankowski Alberta Heart Institute and the Department of Medicine, University of Alberta, Edmonton, Canada (P.R.). 6. Atlanta VA Medical Center, Decatur, GA (J.D.B., A.J.S.).
Abstract
BACKGROUND: Psychological stress is a risk factor for major adverse cardiovascular events (MACE) in individuals with coronary artery disease. Certain brain regions that control both emotional states and cardiac physiology may be involved in this relationship. The rostromedial prefrontal cortex (rmPFC) is an important brain region that processes stress and regulates immune and autonomic functions. Changes in rmPFC activity with emotional stress (reactivity) may be informative of future risk for MACE. METHODS: Participants with stable coronary artery disease underwent acute mental stress testing using a series of standardized speech/arithmetic stressors and simultaneous brain imaging with high-resolution positron emission tomography brain imaging. We defined high rmPFC activation as a difference between stress and control scans greater than the median value for the entire cohort. Interleukin-6 levels 90 minutes after stress, and high-frequency heart rate variability during stress were also assessed. We defined MACE as a composite of cardiovascular death, myocardial infarction, unstable angina with revascularization, and heart failure hospitalization. RESULTS: We studied 148 subjects (69% male) with mean±SD age of 62±8 years. After adjustment for baseline demographics, risk factors, and baseline levels of interleukin-6 and high-frequency heart rate variability, higher rmPFC stress reactivity was independently associated with higher interleukin-6 and lower high-frequency heart rate variability with stress. During a median follow-up of 3 years, 34 subjects (21.3%) experienced a MACE. Each increase of 1 SD in rmPFC activation with mental stress was associated with a 21% increase risk of MACE (hazard ratio, 1.21 [95% CI, 1.08-1.37]). Stress-induced interleukin-6 and high-frequency heart rate variability explained 15.5% and 32.5% of the relationship between rmPFC reactivity and MACE, respectively. Addition of rmPFC reactivity to conventional risk factors improved risk reclassification for MACE prediction, and C-statistic improved from 0.71 to 0.76 (P=0.03). CONCLUSIONS: Greater rmPFC stress reactivity is associated with incident MACE. Immune and autonomic responses to mental stress may play a contributory role.
BACKGROUND: Psychological stress is a risk factor for major adverse cardiovascular events (MACE) in individuals with coronary artery disease. Certain brain regions that control both emotional states and cardiac physiology may be involved in this relationship. The rostromedial prefrontal cortex (rmPFC) is an important brain region that processes stress and regulates immune and autonomic functions. Changes in rmPFC activity with emotional stress (reactivity) may be informative of future risk for MACE. METHODS:Participants with stable coronary artery disease underwent acute mental stress testing using a series of standardized speech/arithmetic stressors and simultaneous brain imaging with high-resolution positron emission tomography brain imaging. We defined high rmPFC activation as a difference between stress and control scans greater than the median value for the entire cohort. Interleukin-6 levels 90 minutes after stress, and high-frequency heart rate variability during stress were also assessed. We defined MACE as a composite of cardiovascular death, myocardial infarction, unstable angina with revascularization, and heart failure hospitalization. RESULTS: We studied 148 subjects (69% male) with mean±SD age of 62±8 years. After adjustment for baseline demographics, risk factors, and baseline levels of interleukin-6 and high-frequency heart rate variability, higher rmPFC stress reactivity was independently associated with higher interleukin-6 and lower high-frequency heart rate variability with stress. During a median follow-up of 3 years, 34 subjects (21.3%) experienced a MACE. Each increase of 1 SD in rmPFC activation with mental stress was associated with a 21% increase risk of MACE (hazard ratio, 1.21 [95% CI, 1.08-1.37]). Stress-induced interleukin-6 and high-frequency heart rate variability explained 15.5% and 32.5% of the relationship between rmPFC reactivity and MACE, respectively. Addition of rmPFC reactivity to conventional risk factors improved risk reclassification for MACE prediction, and C-statistic improved from 0.71 to 0.76 (P=0.03). CONCLUSIONS: Greater rmPFC stress reactivity is associated with incident MACE. Immune and autonomic responses to mental stress may play a contributory role.
Authors: J Douglas Bremner; Carolina Campanella; Zehra Khan; Majid Shah; Muhammad Hammadah; Kobina Wilmot; Ibhar Al Mheid; Bruno B Lima; Ernest V Garcia; Jonathon Nye; Laura Ward; Michael H Kutner; Paolo Raggi; Brad D Pearce; Amit J Shah; Arshed A Quyyumi; Viola Vaccarino Journal: Psychosom Med Date: 2018 Jul/Aug Impact factor: 4.312
Authors: Muhammad Hammadah; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Amit J Shah; Yan Sun; Brad Pearce; Ernest V Garcia; Michael Kutner; J Douglas Bremner; Fabio Esteves; Paolo Raggi; David S Sheps; Viola Vaccarino; Arshed A Quyyumi Journal: Psychosom Med Date: 2017-04 Impact factor: 4.312
Authors: Ashley N Clausen; Alex J Francisco; Joan Thelen; Jared Bruce; Laura E Martin; Joan McDowd; W Kyle Simmons; Robin L Aupperle Journal: Depress Anxiety Date: 2017-03-29 Impact factor: 6.505
Authors: Muhammad Hammadah; Samaah Sullivan; Brad Pearce; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Ayman Samman Tahhan; Wesley T O'Neal; Malik Obideen; Ayman Alkhoder; Naser Abdelhadi; Heval Mohamed Kelli; Mohamad Mazen Ghafeer; Pratik Pimple; Pratik Sandesara; Amit J Shah; Kareem Mohammed Hosny; Laura Ward; Yi-An Ko; Yan V Sun; Lei Weng; Michael Kutner; J Douglas Bremner; David S Sheps; Fabio Esteves; Paolo Raggi; Viola Vaccarino; Arshed A Quyyumi Journal: Brain Behav Immun Date: 2017-10-03 Impact factor: 7.217
Authors: Zakaria Almuwaqqat; Matthew T Wittbrodt; Kasra Moazzami; Jonathan A Nye; Bruno B Lima; Amit J Shah; Jamil Alkhalaf; Brad Pearce; Yan V Sun; Arshed A Quyyumi; Viola Vaccarino; J Douglas Bremner Journal: J Psychosom Res Date: 2022-02-11 Impact factor: 3.006
Authors: Asim H Gazi; Matthew T Wittbrodt; Anna B Harrison; Srirakshaa Sundararaj; Nil Z Gurel; Jonathon A Nye; Amit J Shah; Viola Vaccarino; J Douglas Bremner; Omer T Inan Journal: IEEE Trans Biomed Eng Date: 2022-01-20 Impact factor: 4.538
Authors: Viola Vaccarino; Zakaria Almuwaqqat; Jeong Hwan Kim; Muhammad Hammadah; Amit J Shah; Yi-An Ko; Lisa Elon; Samaah Sullivan; Anish Shah; Ayman Alkhoder; Bruno B Lima; Brad Pearce; Laura Ward; Michael Kutner; Yingtian Hu; Tené T Lewis; Ernest V Garcia; Jonathon Nye; David S Sheps; Paolo Raggi; J Douglas Bremner; Arshed A Quyyumi Journal: JAMA Date: 2021-11-09 Impact factor: 56.272
Authors: Kasra Moazzami; Matthew T Wittbrodt; Bruno B Lima; Jeong Hwan Kim; Zakaria Almuwaqqat; Amit J Shah; Ihab Hajjar; Felicia C Goldstein; Allan I Levey; Jonathon A Nye; J Douglas Bremner; Viola Vaccarino; Arshed A Quyyumi Journal: J Alzheimers Dis Rep Date: 2021-02-02
Authors: Jaskanwal Deep Singh Sara; Takumi Toya; Ali Ahmad; Matthew M Clark; Wesley P Gilliam; Lliach O Lerman; Amir Lerman Journal: Mayo Clin Proc Date: 2022-05 Impact factor: 7.616